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Abstract
Background: Surrogate measures for cardiovascular disease events have the potential to increase
greatly the efficiency of clinical trials. A leading candidate for such a surrogate is the progression of
intima-media thickness (IMT) of the carotid artery; much experience has been gained with this
endpoint in trials of HMG-CoA reductase inhibitors (statins).
Methods and Results: We examine two separate systems of criteria that have been proposed
to define surrogate endpoints, based on clinical and statistical arguments. We use published results
and a formal meta-analysis to evaluate whether progression of carotid IMT meets these criteria for
HMG-CoA reductase inhibitors (statins).
IMT meets clinical-based criteria to serve as a surrogate endpoint for cardiovascular events in statin
trials, based on relative efficiency, linkage to endpoints, and congruency of effects. Results from a
meta-analysis and post-trial follow-up from a single published study suggest that IMT meets
established statistical criteria by accounting for intervention effects in regression models.
Conclusion:  Carotid IMT progression meets accepted definitions of a surrogate for
cardiovascular disease endpoints in statin trials. This does not, however, establish that it may serve
universally as a surrogate marker in trials of other agents.
Atherosclerosis is a generalized disease that causes lesions
in large- and medium-sized elastic and muscular arteries.
As lesions progress, arterial walls are remodeled, a process
through which the size of the arterial lumen is preserved.
Because of this, the disease is clinically asymptomatic dur-
ing its earlier stages and may go unnoticed for decades as
the risk for its clinical manifestation as acute vascular dis-
ease grows [1,2]. Epidemiological studies and interven-
tion trials based on the incidence of acute vascular disease
endpoints require years of follow-up, the participation of
large populations, or both. As a consequence, such studies
consume considerable time and financial resources [3].
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The use of surrogate markers for atherosclerosis extent and
progression is widespread. Currently, the most estab-
lished of these is based on carotid intima-media thickness
(IMT) as measured by B-mode ultrasound. It is a natural
extension to consider these measures as surrogate markers
for cardiovascular disease clinical endpoints [4,5]. If this
extension is valid, the time, expense, and participant bur-
den in understanding and developing treatments to
reduce the risk of clinical endpoints can be reduced. To be
rigorous, this definition must be based on accepted defi-
nitions and/or set of criteria for surrogacy. This document
examines the evidence that carotid IMT, a marker for
atherosclerosis, meets two prominent set of criteria for
defining surrogate outcomes.
Defintions of surrogate markers
Both clinical and statistical criteria for surrogacy have
been proposed.
Clinical Criteria for Surrogacy
Boissel, et al. lay out criteria that markers must meet to be
considered as valid surrogates for clinical endpoints [6].
We group these into three domains.
B1: (Efficiency) The surrogate marker should be relatively
easy to evaluate, preferably by non-invasive means, and
more readily available than the gold standard. The time
course of the surrogate should precede that of the end-
points so that disease and/or disease progression may be
established more quickly via the surrogate. Clinical trials
based on surrogates should require fewer resources, less
participant burden, and a shorter time frame.
B2: (Linkage) The quantitative and qualitative relation-
ship between the surrogate marker and the clinical end-
point should be established based on epidemiological
and clinical studies. The nature of this relationship may be
understood in terms of its pathophysiology or in terms of
an expression of joint risk.
B3: (Congruency) The surrogate should produce parallel
estimates of risk and benefit as endpoints. Individuals
with and without vascular disease should exhibit differ-
ences in surrogate marker measurements. In intervention
studies, anticipated clinical benefits should be deducible
from the observed changes in the surrogate marker.
Statistical Criteria for Surrogacy
Prentice views surrogacy as a statistical property and
defines it with mathematical expressions [7,8]. Four crite-
ria are required for S to serve as a surrogate for endpoint T
with respect to intervention Z.
P1: The intervention should affect the distribution of T.
P2: The intervention should affect the distribution of S.
P3: The distribution of T should be dependent on S.
P4: Endpoint T should be conditionally independent of Z
given S, i.e. S should fully account for the impact of Z on
T.
This definition may be specific to a particular setting and
cohort; a marker may meet the criteria for surrogacy for
one intervention, but fail criteria for others. The criteria
for surrogacy are based on explicit models, and may also
be dependent on covariates and additional explanatory
factors being collected and incorporated into these
models.
Establishing Surrogacy
These clinical and statistical definitions require different
approaches to establish surrogacy, neither of which is
clear-cut. To meet the criteria outlined by Boissel, et al.
[6], experience and data from clinical trials are required to
demonstrate efficiency and congruence, and data from
bench and cohort studies are required to establish plausi-
ble linkage. Arguments for surrogacy address whether
these data are sufficiently compelling. To meet the criteria
outlined by Prentice [7], decisions must be made on the
parametric model describing the relationship between
intervention and outcomes. The plausibility for surrogacy
is argued by the ability of the surrogate marker, once
incorporated in this model, to account (induce condi-
tional independence) for this relationship using experi-
mental data (and by P1 is limited to interventions that
affect outcomes). Since statistical relationships cannot be
established with certainty, arguments are required that the
empirical evidence for conditional independence pro-
vided by data are sufficiently compelling to adopt the
hypothesis of conditional independence required by the
Prentice criteria.
B-mode ultrasound imt
B-mode ultrasound imaging technology has evolved to
the extent that the walls of superficial arteries can be
imaged non-invasively, in real-time, and with high resolu-
tion. Unlike angiography or 'luminology', ultrasound
imaging can visualize the arterial wall at every stage of
atherosclerosis, from 'normal' arterial wall to complete
arterial occlusion. Arterial wall thickness can therefore be
measured as a continuous variable from childhood to old
age, in patients and healthy controls [9]. Studies that have
evaluated the origin of the lumen-intima and the media-
adventitia ultrasound interfaces in relation to carotid and
femoral far-wall arterial histology have demonstrated that
the distance between these interfaces reflects the intima-
media complex. Consequently, this distance is referred toCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:3 http://cvm.controlled-trials.com/content/6/1/3
Page 3 of 6
(page number not for citation purposes)
as IMT [10,11]. IMT has been widely used in both obser-
vational studies and intervention studies.
Surrogacy of carotid imt with respect to statins
We are interested in examining the potential of carotid
IMT to serve as a surrogate marker for cardiovascular
events, in particular cardiovascular mortality, myocardial
infarctions, and clinical stroke. The clinical and statistical
arguments for surrogacy are contextual, i.e. are based on
specific relationships and mechanisms. It is unreasonable
to make open-ended claims that a carotid IMT is a surro-
gate for these endpoints for all interventions and all
cohorts, a point that has not been emphasized
sufficiently.
Our specific focus is to examine surrogacy in clinical trials
of HMG-CoA reductase inhibitors (statins). Empirical evi-
dence is largely drawn from statin clinical trials conducted
on cohorts of adults at elevated risk for cardiovascular
endpoints. Our choice of statins is based, in part, on the
many published trials available for these agents. We
acknowledge that it is quite possible that IMT may be a
valid surrogate for cardiovascular events with respect to
statins (i.e. accounting for the effects of these agents on
cardiovascular events), but may not be a valid surrogate
for other agents (e.g. diuretics or postmenopausal hor-
mone therapy) or endpoints. We used Medline searches to
identify seven placebo-controlled clinical trials of statins
that report both IMT outcomes and cardiovascular events
(see Table 1): the Asympotomatic Carotid Artery Progres-
sion Study (ACAPS), the Kuopio Atherosclerosis Preven-
tion Study (KAPS), the Pravastatin, Lipids, and
Atherosclerosis in the Carotid Arteries Study (PLAC-2),
the Carotid Atherosclerosis Italian Ultrasound Study
(CAIUS), the Regression Growth Evaluation Statin Study
(REGRESS), the Beta-Blocker Cholesterol Lowering
Asymptomatic Plaque Study (BCAPS), and the Fukuoka
Atherosclerosis Trial (FAST) [12-18].
Do IMT measurements meet clinical criteria for surrogate 
markers of cardiovascular disease events?
The three criteria described by Boissel, et al. [6] for surro-
gate markers relate to efficiency, linkage, and congruency
and will be described in turn.
B1: Efficiency
Carotid IMT has been widely used in clinical trials. Relia-
ble protocols have been established for its measurement
and it is arguably more sensitive to the effects of interven-
tions than cardiovascular disease events. Six of seven clin-
ical trials in Table 1 reported a significant beneficial
impact of statins on IMT progression with respect to their
primary IMT outcome measure; the seventh trial, PLAC-II
found no significant impact on its primary IMT outcome
measure, but reported a significant impact on a secondary
IMT measure. In six of seven trials, there were beneficial
trends with respect to reported cardiovascular disease
endpoints; however only for one trial (ACAPS) did this
trend reach nominal statistical significance. Thus, while
IMT measures were sufficiently sensitive so that benefit
could be established within trials of this size, the general
benefit with respect to cardiovascular events could not be
generally established.
B2: Linkage
The strong association between carotid IMT and cardio-
vascular events has been demonstrated repeatedly. For
example, the Cardiovascular Health Study, found it to be
the risk factor most strongly associated with incident car-
diovascular events [19]. In the Rotterdam Study, Del Sol,
et al. found that a single carotid IMT measurement was of
the same importance as a battery of commonly used risk
Table 1: Clinical trials involving HMG-CoA reductase inhibitors and reporting both carotid IMT and cardiovascular event outcomes.
Clinical Trial (N*) Statin Relative Impact on IMT Progression of 
Primary Outcome (mm/yr): Mean [95% CI] 
(reported p-value)
Relative Impact on Reported Cardiovascular 
Endpoints: Odds Ratio [95% CI]
Abstracted CVD Event Odds Ratio
ACAPS(25) (N = 919) Lovastatin -0.015 [-0.023, -0.007] (p = 0.001) CVD Death, MI, Stroke 0.34 [0.12, 0.69]
KAPS(26) (N = 447) Pravastatin -0.014 [-0.022, -0.006] (p = 0.005) CVD Death, MI, Stroke 0.57 [0.22, 1.47]
PLAC-II(47) (N = 151) Pravastatin -0.009 [-0.031, 0.013] (p = 0.44) Clinical Coronary Events 0.37 [0.11, 1.24]
CAIUS(48) (N = 305) Pravastatin -0.014 [-0.021, -0.005] (p = 0.0007) CVD Death, MI 1.02 [0.14, 7.33]
REGRESS(28) (N = 255) Pravastatin -0.030 [-0.056, -0.004] (p = 0.002) Clinical Events 0.51 [0.24, 1.07]
BCAPS(49) (N = 793) Fluvastatin -0.008 [-0.013, -0.003] (p = 0.002) CVD Death, MI, Stroke 0.64 [-0.24, 1.66]
FAST(50) (N = 164) Pravastatin Significant Benefit (p < 0.001) CVD Death, MI 0.32 [0.10, 1.06]
Pooled Estimate -0.012 [-0.016, -0.007]** 0.48 [0.30, 0.78]
*Arms used in meta-analysis; **Excludes FASTCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:3 http://cvm.controlled-trials.com/content/6/1/3
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factors in the prediction of CHD and CVD [20]. The
Atherosclerosis Risk in Communities (ARIC) study found
that carotid IMT of 1 mm or more was associated with two
to five times the increased hazard of CHD and four to
eight times the increased hazard of stroke [21,22]. Using
a nested case-control approach and a mean duration of
follow-up of 2.7 years, the Rotterdam Study found that
per standard deviation increase (0.16 mm) in IMT, the
odds ratio for stroke was 1.41 and for myocardial infarc-
tion was 1.43 [23].
Atherosclerosis is a manifestation of the pathophysiology
underlying cardiovascular disease. The links between
carotid IMT and atherosclerosis are well-established and
IMT measures, as markers of atherosclerosis, have contrib-
uted greatly to the understanding of atherosclerosis pro-
gression [24,25]. These measures have characterized the
role of many risk factors for atherosclerosis and currently
serve the basis for several studies examining its genetics.
The mechanisms by which atherosclerosis is causally
related to cardiovascular events are also well-established.
B3: Congruency
IMT (continuous) and events (categorical) represent dif-
ferent measurement scales, thus it is difficult to argue they
are influenced by statin therapy to quantitatively similar
degrees. We drew evidence that the impacts are qualita-
tively similar using a meta-analysis of the clinical trials
listed in Table 1 and developed pooled estimates of the
relative impact of HMG-CoA reductase inhibitor (statin)
therapy on IMT progression and on the odds ratio of car-
diovascular endpoints [26]. Because standard errors for
IMT changes were not reported for the FAST trial, it was
excluded from this analysis. Across the trials, statin ther-
apy was associated with an average decrease of IMT pro-
gression of 0.012 mm/yr with 95% confidence interval [-
0.016, -0.007]. This pooled estimate confirms with greater
precision the results from the individual trials. More
importantly, the meta-analysis yields a significant odds
ratio of 0.48 [0.30, 0.78] for the reduction cardiovascular
events associated with statin therapy. Thus, a meta-analy-
sis across a number of trials demonstrates a benefit with
respect to cardiovascular disease events that is congruent
with the benefits established by individual IMT trials.
Do IMT measurements meet the criteria of statistical 
criteria for surrogate markers of cardiovascular disease 
events?
The four criteria of Prentice [7] are as follows.
P1: Impact of Interventions on Endpoint
There is convincing evidence, some of which is summa-
rized in the meta-analysis described above, that statin
therapy reduces the risk of cardiovascular events, to the
extent that this is now an indication for their use.
P2: Impact of Interventions on Carotid IMT
As noted above, this association is supported by the
results of our meta-analysis (Table 1) and elsewhere (e.g.
[4]).
P3: Link Between Carotid IMT and Cardiovascular Events
The considerable evidence of this association has been
discussed above.
P4: Conditional Independence Between Statin Therapy and 
Cardiovascular Events Given Carotid IMT
We know of no published literature that examines this
conditional independence for statin therapies. Such a
study is difficult to mount as it requires both sufficient
power to demonstrate the relative impact on IMT progres-
sion of an intervention and sufficient size and follow-up
time after this demonstration to assess the ability of meas-
ured IMT progression to account for subsequent risk. The
only published account to examine the conditional inde-
pendence of cardiovascular events given carotid IMT is for
colestipol-niacin therapy in the Cholesterol Lowering
Atherosclerosis Study (CLAS) clinical trial [27]. The 2-year
CLAS trial demonstrated that colestipol-niacin therapy
reduced IMT progression [28]; the trial cohort was sur-
veyed an average of 8.8 years after the conclusion of CLAS
to tally post-trial incidence of coronary events (nonfatal
MI, coronary death, and coronary artery revasculariza-
tion). These investigators found that while treatment
assignment, by itself, was significantly related to occur-
rence of these events (relative risk 0.41; p = 0.01), when
on-study IMT progression was included as a covariate, this
relationship evaporated (relative risk 1.1; p > 0.2). Fried-
man, et al. use the term proportion of treatment effect cap-
tured (PTE) to describe how well a surrogate marker meets
criterion P4 [29]; at face value, the findings from CLAS
produce an estimate that PTE exceeds 1.
In our meta-analysis, when IMT progression is included as
a covariate in regression models linking cardiovascular
disease events to statin treatment, the relative odds ratio is
mediated from 0.48 (as tabulated below) to 0.64 and is
no longer statistically significant (p = 0.13). This suggests
that changes in IMT may account for some, but not all, of
the effect of statins on cardiovascular events (i.e. a PTE of
0.3). Several issues complicate this argument, however.
Even if a surrogate successfully meets Prentice's criteria for
surrogacy within individual trials, because designs,
cohorts, and endpoints vary it is to be expected that a sur-
rogate would only account for some, not all, of treatment
effects in regression models across trials. Secondly, like
many markers, IMT is subject to measurement error and
that is not insubstantial. This measurement error, if
uncorrected, may lead to marked underestimates of rela-
tionships [30]: measured IMT progression may appear to
account for less of the relationship between interventionsCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:3 http://cvm.controlled-trials.com/content/6/1/3
Page 5 of 6
(page number not for citation purposes)
and events than true progression. These issues obscure the
validation of surrogacy from meta-analyses based on pub-
lished summary statistics. We can only conclude that IMT
progression may account for at least some of the treat-
ment effects attributable to statin therapy, but that it is dif-
ficult to quantitate the degree of this relationship and that
full surrogacy cannot be ruled out.
Summary
We have examined, in a structured and rigorous manner,
the evidence that carotid IMT progression may serve as a
surrogate for cardiovascular disease endpoints in statin tri-
als. Each of the criteria for surrogacy described by Boissel,
et al. appears to be met. The first three of Prentice's criteria
are met, and the fourth is met by the one published study
for which it can be evaluated (although not for statin ther-
apy). Meta-analyses of statin trials provide support for
Boissel's criteria and the first three of Prentice's criteria,
and are not inconsistent for Prentice's fourth criterion.
It is possible that these arguments may generalize to other
agents whose mechanisms are similar to statins, however
additional analyses, based on criteria for surrogate out-
comes, would be required to make this extension.
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